Benefits
Traditional diuretic used for fluid balance and urinary support
Older Chinese clinical reports described Polyporus umbellatus as a diuretic used within traditional fluid-balance and urinary-support practice. These reports are dated and low-quality by modern methodological standards; pyelonephritis, nephritis and urolithiasis are diagnosed medical conditions, and this is not evidence that the mushroom treats them.
Chronic hepatitis B (9-RCT systematic review, 936 patients)
A systematic review of 9 RCTs (936 patients) reported PUPS positive HBeAg clearance vs placebo (RR 3.06, 95% CI 1.13-8.29) and HBV DNA clearance vs non-specific treatment (RR 4.14, 95% CI 1.00-17.19) in chronic hepatitis B. Reported for transparency, not as an endorsement: these were small, low-quality Chinese TCM trials, and the review itself rated overall evidence quality as low — rigorous double-blind placebo-controlled trials are still needed. Chronic hepatitis B is a viral disease requiring medical care.
Xiong 1993 chronic HBV combination RCT
A randomized trial compared Dan Shen + PUPS vs each alone in chronic HBV. Combination context — most clinical evidence is in TCM combination formulas rather than isolated PUPS.
Anti-aldosteronic diuretic mechanism (ergone)
Ergone has anti-aldosteronic diuretic activity by blocking aldosterone (the sodium/potassium-regulating mineralocorticoid). A distinguishing mechanism vs osmotic or loop diuretics, and the biochemically interesting basis for the traditional diuretic action.
Anti-cachexia polysaccharide — preclinical/animal (Wu 1997)
PUPS inhibits cachexia induced by toxohormone-L. This is a preclinical (animal model) finding only. There is no human evidence that Polyporus umbellatus prevents, treats, or supports treatment of cancer, and it should not be read as an anticancer benefit.
Antioxidant triterpenes
Zhuling protected red blood cells from AAPH-induced hemolysis (50-1000 µg/mL dose-dependent). Polyporusterones A and B are free radical scavengers; polyporusterone B is significantly stronger than A. 150 mg ingestion increased plasma free-radical scavenging in rats.
Renal fibrosis protection
Preclinical evidence that Polyporus umbellatus protects against renal fibrosis by regulating intrarenal fatty acyl metabolites. Mechanistic finding pending clinical translation in chronic kidney disease populations.
Mechanism of action
Anti-aldosteronic diuretic activity (ergone)
Ergone blocks aldosterone, the mineralocorticoid hormone regulating sodium and potassium. Distinguishing pharmacology from osmotic or loop diuretics; mechanistically resembles spironolactone-class diuretics at the receptor level.
PUPS β-glucan immunomodulation
PUPS — β-glucan with (1-3) backbone and (1-6) side chains, MW ~1.6×10⁵ Da — binds Dectin-1 receptors on innate immune cells. Foundational mushroom β-glucan immunomodulation pathway.
Polyporusterone A and B antioxidant triterpenes
Triterpene carboxylic acids with free radical scavenging activity. Polyporusterone B is significantly more potent than A, with demonstrated dose-dependent protection of red blood cells from AAPH-induced hemolysis.
Anti-cachexic polysaccharide
PUPS inhibits cachexia induced by toxohormone-L. Polysaccharide-based mechanism distinct from the small-molecule activities of ergone or polyporusterones.
Renal fibrosis protection (preclinical)
Protection against renal fibrosis via regulation of intrarenal fatty acyl metabolites. Lipid-metabolism mechanism in animal models; not yet translated to clinical CKD endpoints.
Radio- and chemoprotective effects
Polyporus extracts have shown radio- and chemoprotective effects in human cultured cells and mice. This is a preclinical observation in cultured cells and mice only, not a basis for any oncology use in people.
Clinical trials
Clinical studies confirmed Polyporus umbellatus is an effective diuretic for pyelonephritis, nephritis, and urolithiasis without notable side effects.
Clinical population described in trial publication.
Dated Chinese clinical reports described a diuretic effect consistent with traditional fluid-balance and urinary-support use. Methodology is weak by modern standards, and these reports do not establish that the mushroom treats pyelonephritis, nephritis, or urolithiasis — diagnosed conditions requiring medical care.
Evidence review of 9 clinical trials (n=936) — PUPS showed positive HBeAg clearance vs placebo (RR 3.06, 95% CI 1.13-8.29) and HBV DNA clearance vs non-specific treatment (RR 4.14, 95% CI 1.00-17.19).
9 clinical trials pooled
Evidence review of 9 clinical trials (n=936) — PUPS showed positive HBeAg clearance vs placebo (RR 3.06, 95% CI 1.13-8.29) and HBV DNA clearance vs non-specific treatment (RR 4.14, 95% CI 1.00-17.19). Critical limitation acknowledged in the review itself: overall evidence quality is low, with rigorous double-blind placebo-controlled trials still needed.
Zhongguo Zhong Xi Yi Jie He Za Zhi 13:533-535 — 90-patient clinical trial comparing Dan Shen + PUPS vs each component alone in chronic HBV.
Clinical population described in trial publication.
Zhongguo Zhong Xi Yi Jie He Za Zhi 13:533-535 — 90-patient clinical trial comparing Dan Shen + PUPS vs each component alone in chronic HBV. Most Polyporus clinical evidence is in TCM combination formulas (Wuling San, Si Ling San, Dan Shen + PUPS) rather than isolated PUPS.